These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF. Ji C; Xue GF; Lijun C; Feng P; Li D; Li L; Li G; Hölscher C Brain Res; 2016 Mar; 1634():1-11. PubMed ID: 26453833 [TBL] [Abstract][Full Text] [Related]
10. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease. Yuan Z; Li D; Feng P; Xue G; Ji C; Li G; Hölscher C Eur J Pharmacol; 2017 Oct; 812():82-90. PubMed ID: 28666800 [TBL] [Abstract][Full Text] [Related]
11. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease. Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury. Bader M; Li Y; Lecca D; Rubovitch V; Tweedie D; Glotfelty E; Rachmany L; Kim HK; Choi HI; Hoffer BJ; Pick CG; Greig NH; Kim DS Neurobiol Dis; 2019 Apr; 124():439-453. PubMed ID: 30471415 [TBL] [Abstract][Full Text] [Related]
13. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'. Skow MA; Bergmann NC; Knop FK Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961 [TBL] [Abstract][Full Text] [Related]
14. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Fisman EZ; Tenenbaum A Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089 [TBL] [Abstract][Full Text] [Related]
15. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies. Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940 [TBL] [Abstract][Full Text] [Related]
16. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation. Mayendraraj A; Rosenkilde MM; Gasbjerg LS Peptides; 2022 May; 151():170749. PubMed ID: 35065096 [TBL] [Abstract][Full Text] [Related]
17. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Ferrari F; Moretti A; Villa RF Pharmacol Ther; 2022 Nov; 239():108277. PubMed ID: 36064147 [TBL] [Abstract][Full Text] [Related]
18. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Nauck MA; Quast DR; Wefers J; Pfeiffer AFH Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013 [TBL] [Abstract][Full Text] [Related]
19. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Hansotia T; Drucker DJ Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432 [TBL] [Abstract][Full Text] [Related]
20. Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury. Glotfelty EJ; Delgado T; Tovar-Y-Romo LB; Luo Y; Hoffer B; Olson L; Karlsson T; Mattson MP; Harvey B; Tweedie D; Li Y; Greig NH ACS Pharmacol Transl Sci; 2019 Apr; 2(2):66-91. PubMed ID: 31396586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]